Skip to main content
$0.080 0.005 (6.67%)

High

$0.08

Low

$0.08

Trades

10

Turnover

$19,245

Volume

244,049
30 June 2023 at 1:52pm
If you were already registered, log in here.

Short Interest

ASIC data, 3 Jul 2026

% Shorted

0.00% 0.01
vs 0.01% prior report

Most Shorted Rank

699th
of 717 shorted ASX stocks

Peak Short

0.02%
Mar 2021

Days to Cover

0.0
at 50d avg vol
Subject
NSB Ann: Change of Director's Interest Notice - Rennie

NSB Ann: Change of Director's Interest Notice - Uvarov

NSB Ann: Change of Director's Interest Notice - Rennie

NSB Ann: Change of Director's Interest Notice - Uvarov

NSB Ann: Change of Director's Interest Notice - Rennie

NSB Ann: Quarterly Activities/Appendix 4C Cash Flow Report

NSB Ann: Positive treatment effect in MS animal study

NSB Ann: Half Yearly Report and Accounts

NSB Ann: Notification of cessation of securities - NSB

NSB Ann: Investor Update Presentation

NSB Ann: Investor Update Webinar

NSB Ann: R&D Tax Incentive Refund Received

NSB Ann: Quarterly Activities/Appendix 4C Cash Flow Report

NSB Ann: Patent Application - Updated Announcement

NSB Ann: NSB files new patent

NSB Ann: Results of Meeting

NSB Ann: Chair's address to shareholders & AGM presentation

NSB Ann: Appointment of Interim CEO

NSB Ann: Executive Management Changes

NSB Ann: NSB receives R&D Advance & Overseas Finding

NSB Ann: Quarterly Activities/Appendix 4C Cash Flow Report

NSB Ann: Notice of Annual General Meeting

NSB Ann: Investor Update Presentation

NSB Ann: Investor Update Webinar

NSB Ann: Final Director's Interest Notice - Liddelow

NSB Ann: CEO Resignation

NSB Ann: Investor Update Webinar

NSB Ann: HREC decision to not approve Phase I Clinical Trial

NSB Ann: Corporate Governance Statement

NSB Ann: Appendix 4G

NSB Ann: NeuroScientific releases FY2022 Results

NSB Ann: 2022 Annual Report and Appendix 4E

NSB Ann: R&D Tax Incentive Refund Received

NSB Ann: Quarterly Activities/Appendix 4C Cash Flow Report

NSB Ann: HREC Submission for Phase I Clinical Trial

NSB Ann: First Subject Recruited for Early-Phase Clinical Trial

NSB Ann: Notification of cessation of securities - NSB

NSB Ann: Company Presentation - Gold Coast Investment Showcase

NSB Ann: Clarification of Results in MS Animal Study

NSB Ann: Notification regarding unquoted securities - NSB

NSB Ann: Issue of Employee Options

NSB Ann: Positive results in MS animal study

NSB Ann: Ethics Approval Granted for Early-Phase Clinical Trial

NSB Ann: HREC Submission for early-phase Clinical Trial

NSB Ann: Quarterly Activities/Appendix 4C Cash Flow Report

NSB Ann: Positive safety result supports advance to clinical trials

NSB Ann: NSB Enhances Management Team

NSB Ann: Company Presentation

NSB Ann: NSB presenting at Broker Briefing Investor Webinar

NSB Ann: New data demonstrates EmtinB activity in autoimmune diseases

If you were already registered, log in here.

Similar Companies

CSL ...
CSL
CUV
IMM
IMU
MSB
OPT
PAR
PYC
RAC
TLX
S88
MAV
ATW $7.5m raise
RDO $30m raise
ABC $5m raise
RGS
MBM